<DOC>
	<DOC>NCT00613002</DOC>
	<brief_summary>This study is a randomized, double-blind, placebo-controlled, multi-center study of the safety and efficacy of LibiGel® 300mcg in the treatment of HSDD in surgically menopausal women</brief_summary>
	<brief_title>Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Hypokinesia</mesh_term>
	<mesh_term>Sexual Dysfunctions, Psychological</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Must be between the ages of 30 to 65 years Must have undergone hysterectomy and bilateral salpingooophorectomy A history of allergic reactions to androgens (oral or patch), topical alcohol, or any component of the formulation Any systemic skin diseases or local skin abnormalities in the area of application Diagnosed with another primary female sexual dysfunction (e.g., Sexual Aversion Disorder, Female Sexual Arousal Disorder). A medical condition that could affect or interfere with sexual function Using a systemic topical gel or cream estrogen therapy.</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>hypoactive sexual desire disorder</keyword>
	<keyword>testosterone</keyword>
	<keyword>menopause</keyword>
</DOC>